Elizabeth Holmes’ partner is securing substantial funding for a new blood-testing startup.
Billy Evans, the long-term partner of Elizabeth Holmes, has reportedly secured significant funding for a new diagnostics startup named Haemanthus, described as pioneering a novel approach to health testing. The initiative aims to develop advanced diagnostic tools that harness artificial intelligence to enhance health assessments.
Evans, who has two children with Holmes, is at the forefront of this new venture, which has garnered attention for its ambition to deliver revolutionary healthcare solutions. According to reports, the company is striving to introduce a sophisticated product intended to serve as a potent diagnostic instrument that could alter the landscape of health monitoring and disease detection.
Holmes, once a celebrated figure in Silicon Valley as the founder of Theranos, has since faced legal repercussions, culminating in her conviction for investor fraud. In November 2022, she was sentenced to over 11 years in federal prison for misleading investors regarding her company’s technology, which claimed to conduct comprehensive blood tests using merely a drop of blood. Prominent figures in the investment community, including media tycoon Rupert Murdoch and Oracle co-founder Larry Ellison, had previously backed Theranos with nearly billion, drawn by its seemingly groundbreaking promise.
Despite the controversy surrounding her past, Holmes reportedly continues to contribute to Evans’s endeavors from her minimum-security prison location in Bryan, Texas. Reports indicate she provides insights and advice as he leads the development of Haemanthus. The startup aims to focus on the optimization of human health, aiming to extend beyond blood testing by incorporating saliva and urine analysis.
The proposed device, which draws inspiration from Theranos’ now-infamous “Edison” blood-testing technology, utilizes light-detection technology to execute medical evaluations, following the patent it received earlier this year. Such innovations signal a dedication to advancing diagnostic accuracy and reliability within the healthcare sector.
As Haemanthus prepares to enter a competitive market for diagnostic devices, the company’s emphasis on integrating artificial intelligence positions it strategically in an evolving industry that increasingly seeks technology-driven solutions for health assessment. The forthcoming developments from Evans’s startup will be watched closely as they emerge from the shadow of Theranos, potentially reshaping public and investor perceptions in the diagnostic sector.
Media News Source
